Rein Therapeutics Inc [NASDAQ: RNTX] stock went on an upward path that rose over 11.82% on Monday, amounting to a one-week price increase of more than 29.63%.
Over the last 12 months, RNTX stock dropped by -23.91%. The one-year Rein Therapeutics Inc stock forecast points to a potential upside of 79.41. The average equity rating for RNTX stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $41.21 million, with 23.05 million shares outstanding and 21.66 million shares in the current float. Compared to the average trading volume of 159.59K shares, RNTX stock reached a trading volume of 45746175 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Rein Therapeutics Inc [RNTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RNTX shares is $8.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RNTX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Rein Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 22, 2025. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on January 28, 2025, representing the official price target for Rein Therapeutics Inc stock.
The Price to Book ratio for the last quarter was 13.41, with the Price to Cash per share for the same quarter was set at 0.24.
RNTX Stock Performance Analysis:
Rein Therapeutics Inc [RNTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 29.63. With this latest performance, RNTX shares gained by 47.06% in over the last four-week period, additionally sinking by -2.78% over the last 6 months – not to mention a drop of -23.91% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RNTX stock in for the last two-week period is set at 71.69, with the RSI for the last a single of trading hit 0.1917, and the three-weeks RSI is set at 0.1497 for Rein Therapeutics Inc [RNTX]. The present Moving Average for the last 50 days of trading for this stock 1.2708, while it was recorded at 1.5470 for the last single week of trading, and 1.6521 for the last 200 days.
Rein Therapeutics Inc (RNTX) Capital Structure & Debt Analysis
According to recent financial data for Rein Therapeutics Inc. ( RNTX), the Return on Equity (ROE) stands at -79.38%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -70.89%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Rein Therapeutics Inc’s Return on Invested Capital (ROIC) is -123.20%, showcasing its effectiveness in deploying capital for earnings.
Rein Therapeutics Inc (RNTX) Efficiency & Liquidity Metrics
Based on Rein Therapeutics Inc’s (RNTX) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Rein Therapeutics Inc (RNTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Rein Therapeutics Inc. (RNTX) effectively leverages its workforce, generating an average of -$5377272.73 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.86% and a Quick Ratio of 0.86%, indicating strong ability to cover short-term liabilities.
RNTX Stock EPS
With the latest financial reports released by the company, Rein Therapeutics Inc posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.45/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.18. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RNTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Rein Therapeutics Inc go to 34.86%.
Rein Therapeutics Inc [RNTX] Institutonal Ownership Details
There are presently around $32.52%, or 32.55%% of RNTX stock, in the hands of institutional investors.
